Healio Pulmonology highlighted new results from the EMPROVE trial that were presented at the European Respiratory Society International Congress. Patients with severe heterogeneous emphysema treated with the Spiration Valve System had a sustained clinically significant benefit in health-related quality of life at 24 months. The article included comments from Gerard J. Criner, MD, FACP, FACCP, Chair and Professor of Thoracic Medicine and Surgery at the Lewis Katz School of Medicine at Temple University and Director of the Temple Lung Center.